{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:35:23Z","timestamp":1792157723493,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.modpat.2025.100781","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T19:25:45Z","timestamp":1744917945000},"page":"100781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8505-4603","authenticated-orcid":false,"given":"Jan Niklas","family":"Mink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oybek","family":"Khalmurzaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Pryalukhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Geppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristof","family":"Bende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen","family":"Loertzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Heinzelbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer M.","family":"Bohle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"St\u00f6ckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vsevolod","family":"Matveev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2025.100781_bib1","doi-asserted-by":"crossref","unstructured":"de Vries HM, Rafael TS, Gil-Jimenez A, et al. Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (the PERICLES study): a phase II trial. J Clin Oncol. 41(31):4872-4880. https:\/\/doi.org\/10.1200\/JCO.22.02894.","DOI":"10.1200\/JCO.22.02894"},{"issue":"12","key":"10.1016\/j.modpat.2025.100781_bib2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/jnci\/djad155","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors","volume":"115","author":"El Zarif","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.modpat.2025.100781_bib3","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.modpat.2025.100781_bib4","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.modpat.2025.100781_bib5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"10411","key":"10.1016\/j.modpat.2025.100781_bib6","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.modpat.2025.100781_bib7","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3390\/ijms22020976","article-title":"NECTIN4: a novel therapeutic target for melanoma","volume":"22","author":"Tanaka","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.modpat.2025.100781_bib8","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","article-title":"Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer","volume":"69","author":"Takano","year":"2009","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.modpat.2025.100781_bib9","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1101\/gad.196451.112","article-title":"Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via \u03b2-catenin signaling","volume":"26","author":"Stoyanova","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.modpat.2025.100781_bib10","doi-asserted-by":"crossref","unstructured":"Kl\u00fcmper N, Tran NK, Zsch\u00e4bitz S, et al. NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer. J Clin Oncol. 42(20):2446-2455. https:\/\/doi.org\/10.1200\/JCO.23.01983.","DOI":"10.1200\/JCO.2024.42.4_suppl.673"},{"key":"10.1016\/j.modpat.2025.100781_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2022.12.008","article-title":"An analysis of Nectin-4 (PVRL4) in penile squamous cell carcinoma","volume":"49","author":"Grass","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.modpat.2025.100781_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.humpath.2023.10.003","article-title":"Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma","volume":"142","author":"Tekin","year":"2023","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2025.100781_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"issue":"19","key":"10.1016\/j.modpat.2025.100781_bib14","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.3390\/cancers15194748","article-title":"Evaluation of prognostic parameters to identify aggressive penile carcinomas","volume":"15","author":"Mink","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.modpat.2025.100781_bib15","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.modpat.2025.100781_bib16","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.modpat.2025.100781_bib17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/PAS.0b013e31819d17eb","article-title":"The prognostic index: a useful pathologic guide for prediction of nodal metastases and survival in penile squamous cell carcinoma","volume":"33","author":"Chaux","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.modpat.2025.100781_bib18","first-page":"1391","article-title":"Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs\u2019 development","volume":"128","author":"Moretto","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.modpat.2025.100781_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154416","article-title":"The prognostic significance of Nectin-2 and Nectin-4 expression in glial tumors","volume":"244","author":"Dekani\u0107","year":"2023","journal-title":"Pathol Res Pract"},{"issue":"22","key":"10.1016\/j.modpat.2025.100781_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216109","article-title":"Metastatic penile squamous cell carcinoma responsive to enfortumab vedotin","volume":"24","author":"Fahey","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.modpat.2025.100781_bib21","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.18632\/oncotarget.28299","article-title":"Nectin-4 is widely expressed in head and neck squamous cell carcinoma","volume":"13","author":"Sanders","year":"2022","journal-title":"Oncotarget"},{"key":"10.1016\/j.modpat.2025.100781_bib22","doi-asserted-by":"crossref","unstructured":"Elst L, Philips G, Vandermaesen K, et al. Single-cell atlas of penile cancer reveals TP53 mutations as a driver of an aggressive phenotype, irrespective of human papillomavirus status, and provides clues for treatment personalization. Eur Urol. 86(2):114-127. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.038.","DOI":"10.1016\/j.eururo.2024.03.038"},{"issue":"4","key":"10.1016\/j.modpat.2025.100781_bib23","first-page":"274","article-title":"[Importance of HPV status and p16 for the prognosis of penile carcinoma]","volume":"54","author":"Mink","year":"2023","journal-title":"Aktuelle Urol"},{"issue":"9","key":"10.1016\/j.modpat.2025.100781_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075864","article-title":"Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.modpat.2025.100781_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"},{"issue":"11","key":"10.1016\/j.modpat.2025.100781_bib26","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.1007\/s00432-023-04761-8","article-title":"TROP-2 is widely expressed in vulvar squamous cell carcinoma and represents a potential new therapeutic target","volume":"149","author":"Condic","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100781_bib27","doi-asserted-by":"crossref","unstructured":"Weiten R, Storz E, Kessler C, et al. Trophoblast cell surface antigen-2: a promising new biomarker and potential therapeutic target in penile squamous cell carcinoma. BJU Int. 134(4):615-621. https:\/\/doi.org\/10.1111\/bju.16442.","DOI":"10.1111\/bju.16442"},{"issue":"4","key":"10.1016\/j.modpat.2025.100781_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The anti-nectin 4: a promising tumor cells target. A systematic review","volume":"21","author":"Bouleftour","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.modpat.2025.100781_bib29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/1878-0261.12627","article-title":"Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo","volume":"14","author":"Perrone","year":"2020","journal-title":"Mol Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2025.100781_bib30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ygyno.2019.11.018","article-title":"In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma","volume":"156","author":"Han","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"15","key":"10.1016\/j.modpat.2025.100781_bib31","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","article-title":"Sacituzumab govitecan demonstrates efficacy across tumor Trop-2 expression levels in patients with advanced urothelial cancer","volume":"30","author":"Loriot","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.modpat.2025.100781_bib32","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/hed.23138","article-title":"Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma","volume":"35","author":"Wu","year":"2013","journal-title":"Head Neck"},{"issue":"10","key":"10.1016\/j.modpat.2025.100781_bib33","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/1055-9965.EPI-18-0322","article-title":"Prognostic significance of HPV and p16 status in men diagnosed with penile cancer: a systematic review and meta-analysis","volume":"27","author":"Sand","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.modpat.2025.100781_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/adj.12652","article-title":"Human papillomavirus and oral and oropharyngeal carcinoma: the essentials","volume":"64","author":"Yakin","year":"2019","journal-title":"Aust Dent J"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225000778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225000778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:00:36Z","timestamp":1762315236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395225000778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0893395225000778"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100781","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100781"}}